|
Cinacalcet for hyperparathyroidism trial results published in NEJM. |
 |
 |
|
NEJM: Results Forty-three percent of the cinacalcet group reached the primary end point, as compared with 5 percent of the placebo group (P<0.001). Overall, mean parathyroid hormone values decreased 43 percent in those receiving cinacalcet but increased 9 percent in the placebo group (P<0.001). The serum calcium–phosphorus product declined by 15 percent in the cinacalcet group and remained unchanged in the placebo group (P<0.001). Cinacalcet effectively reduced parathyroid hormone levels independently of disease severity or changes in vitamin D sterol dose.
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
